Results 151 to 160 of about 53,515 (238)
Impact of Organ-Specific Severe Immune-Related Adverse Events on Long-Term Survival and Treatment Transitions in Metastatic Renal Cell Carcinoma: A 5-Year Multicenter Multistate Analysis. [PDF]
Tasaki Y +19 more
europepmc +1 more source
Intratumoral CTLA‐4 Blockade: Decoupling Local Immune Remodeling From Systemic Toxicity
MedComm – Oncology, Volume 5, Issue 4, December 2026.
Luyan Chen +4 more
wiley +1 more source
ABSTRACT A 59‐year‐old man with recurrent gastric cancer began nivolumab as third‐line therapy and subsequently experienced joint pain and dry eyes. Symptoms worsened despite NSAIDs. He was diagnosed with rheumatoid arthritis and Sjögren's syndrome, associated with nivolumab, and was successfully treated with immunosuppressive and anti‐rheumatic ...
Haruhiko Takemoto +7 more
wiley +1 more source
Pembrolizumab Activity in Tyrosine Kinase Inhibitor–Refractory Metastatic GIST: A Case Report
ABSTRACT Introduction Gastrointestinal stromal tumors (GISTs) are commonly driven by activating mutations in KIT or PDGFRA. Although sequential tyrosine kinase inhibitors (TKIs) have improved outcomes in advanced disease, acquired resistance is common.
Neharika Bandaru +2 more
wiley +1 more source
Currently, there are at least 30 ongoing clinical trials in the enrollment phase to evaluate adding concurrent ICIs to the PACIFIC regimen for a variety of solid tumors. Considering the lack of head‐to‐head comparative studies, this meta‐analysis aims to investigate the differences in efficacy between adding and not adding concurrent ICIs to CRT ...
Xu Tong +4 more
wiley +1 more source
Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis. [PDF]
Nishio M +14 more
europepmc +1 more source
The Effect of Ipilimumab on the Endocrine Function
Class of 2016 AbstractObjectives: To test whether ipilimumab therapy affects the endocrine system in patients with Metastatic Melanoma. Methods: A retrospective chart review was performed that included patients with Metastatic Melanoma that had at least ...
Qyra, Ollga, McBride, Ali
core
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel +26 more
wiley +1 more source
Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial. [PDF]
Ruffin AT +26 more
europepmc +1 more source
ABSTRACT Introduction Renal cell carcinoma (RCC) is the most common primary site of pancreatic metastases, and complete resection confers a favorable prognosis. Lenvatinib plus pembrolizumab (LEN + PEM) is standard first‐line therapy for advanced RCC; however, induction therapy before resection of pancreatic metastasis has not been reported.
Yuta Kaneko +9 more
wiley +1 more source

